Funding Friday 02/26/2021 Edition 22
----- Office of Sponsored Programs -----
Please forward and share with other faculty who may be interested.
NSF Mid-Career Advancement (MCA) - NSF 21-516
Full Proposal Due: 02/07/2022

An academic career often does not provide the uninterrupted stretches of time necessary for acquiring and building new skills to enhance and
advance one's research program. Mid-career scientists in particular are at a critical career stage where they need to advance their research programs to ensure long-term productivity and creativity but are often constrained by service, teaching, or other activities that limit the amount of time devoted to research.

The MCA offers an opportunity for scientists and engineers at the Associate Professor rank (or equivalent) to substantively enhance and advance their research program through synergistic and mutually beneficial partnerships, typically at an institution other than their home institution. Projects that envision new insights on existing problems or identify new but related problems previously inaccessible without new methodology or expertise from other fields are encouraged.

Partners from outside the PI's own sub-discipline or discipline are encouraged, but not required, to enhance interdisciplinary networking and convergence across science and engineering fields.

By (re)-investing in mid-career investigators, NSF aims to enable and grow a more diverse scientific workforce (more women, persons with disabilities, and underrepresented minorities) at high academic ranks, who remain engaged and active in cutting-edge research.
NIH Innovation for Tuberculosis Vaccine Discovery (ITVD) (R61/R33 Clinical Trial Not Allowed): RFA-AI-21-007
Application Due: 06/30/2021

To support the design of novel tuberculosis (TB) vaccine candidates that exploit innovative approaches and their advancement into preclinical animal model testing. This funding opportunity will use a milestone driven, biphasic award mechanism to fund high risk/exploratory research. Transition to the second phase depends on the successful completion of milestones.
HRSA Bridging the Word Gap Research Network (BWG): HRSA-21-040 Application Due: 04/22/2021
Up to $300,000/yr for 3 years

The purpose of this program is to establish and maintain a national, multi-site, collaborative Research Network to develop, test, and promote effective interventions for supporting the enrichment of the early (ages 0-5 years) home learning environments of children from underserved families for whom there are limited interventions or existing interventions are ineffective.
FDA Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01) Clinical Trials Not Required: RFA-FD-22-001
Application Due: 02/15/2022

The purpose of this funding opportunity announcement (FOA) is to support efficient and innovative natural history studies that advance medical product development in rare diseases/conditions with unmet needs. Through the support of natural history studies with high quality and interpretable data elements, FDA expects to address critical knowledge gaps, remove major barriers to progress in the field, exert a significant and broad impact on a specific rare disease or multiple rare diseases with similar pathophysiology, and facilitate rare disease product development.
Request for Proposals (RFP) Education and Support for Patients with Locally-Advanced or Metastatic Bladder Cancer Application Due Date: 04/07/2021  Learn More

The intent of this RFP is to support independent education initiatives for patients with locally-advanced or metastatic bladder cancer and their caregivers. The goal is to increase understanding of 1st line maintenance treatment and overall treatment options in the 1st line setting for locally-advanced or metastatic bladder cancer.

Grants available to patient-focused organizations working in the bladder cancer area interested in developing educational materials or resources for patients including:
  • Novel decision making tools to support provider-patient decision making and drive patient engagement in their care.
  • Innovative communication channels, digital programs, and enduring resources.
Request for Proposals (RFP) Pre-clinical & Translational Research in Multiple Myeloma
Application Due Date: 05/17/2021  Learn More

Only pre-clinical projects with a focus on these areas of interest will be considered for Pfizer support at this time:
  • Correlation between soluble B-cell Maturation Antigen (sBCMA) at baseline with FLC, M-spike, deepness of overall response, MRD-negativity, and response to prior therapy
  • Understanding the kinetics of sBCMA vs long-term responses (e.g., DoR, PFS, OS)
  • Mechanisms of resistance (e.g., role of sBCMA in resistance/relapse; downregulation of membrane bound BCMA; T-cell exhaustion)
  • Correlation between Soluble BCMA and BCMA expression on myeloma cells
  • Impact of prior treatment with BCMA-targeting agents on BCMA expression and sBCMA levels
  • Mechanistic understanding of the impact of anti-myeloma agents (e.g., IMiDs, anti-CD38, proteasome inhibitors, dexamethasone) on elranatamab-mediated T-cell activation and anti-myeloma activity
  • Exploring in-vitro or in-vivo novel combinations with elranatamab (PF-06863135)
Althea Sheets, Communications Manager, Office of Sponsored Programs, [email protected], 702-895-1880